On September 14, DUALITYBIO-B rose 10.55% in regular trading, reaching HKD 186.5 per share with turnover of HKD 187 million. The rally was driven by updated clinical data presented at the World Lung Cancer Congress (WCLC).

Specifically, DUALITYBIO-B and BioNTech disclosed Phase Ib/II results for B7-H3 ADC BNT324/DB-1311 in combination with PD-L1 x VEGF-A bispecific antibody Pumitamig in advanced lung cancer. As of July 7, among 71 evaluable small cell lung cancer patients, the overall objective response rate reached 70.4%, with a striking 92.3% ORR in the first-line setting, 77.3% in second-line, and 52.4% in third-line and beyond. DB-1311 is considered the company's core value driver, with UBS initiating coverage at a Buy rating and a target price of HKD 320, projecting peak sales of RMB 38.3 billion. The data release comes amid broader positive momentum, including a recently signed global collaboration with Roche's Genentech on the DUPAC payload platform worth over USD 1 billion in potential milestones, and consecutive insider purchases by Chairman Zhu Zhongyuan.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)